Drug Development RFP
Funds IND-enabling studies and early-phase clinical trials for innovative drug and device therapies for Alzheimer’s disease, focusing on novel mechanisms, robust data, and translational research.
Funder: Alzheimer's Drug Discovery Foundation
Due Dates: September 14, 2026: Letter of Intent deadline
Funding Amounts: Up to $5,000,000 per project; multi-year awards; milestone-based payments
Summary: Supports IND-enabling studies and early-phase clinical trials for innovative pharmacological and device-based therapies targeting Alzheimer’s disease and related dementias.
Key Information: Anti-amyloid and cholinesterase inhibitor proposals are not eligible; only direct costs allowed.
Description
This opportunity funds investigational new drug (IND)-enabling studies and early-phase clinical trials for promising pharmacological interventions and devices targeting Alzheimer’s disease and related dementias. The focus is on advancing novel drug mechanisms and modes of action, especially those related to the biology of aging and emerging therapeutic areas. Priority is given to combination therapies, disease-modifying and symptomatic agents, and both novel or repurposed drugs (including small molecules, peptides, antibodies, gene therapies, antisense oligonucleotides, and stem cells). Proposals must demonstrate compelling biological rationale, robust preliminary data, and a clear justification for the study design and clinical population. Biomarker-based proof-of-concept studies are encouraged. Intellectual property development and collaborative research are emphasized.
